Here are the S-3 shelf registrations from Tessera Defense and Homeland Security Inc. (HLSQ) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow HLSQ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HLSQ filings page.
BiomX Inc. is registering up to 5,310,933 shares of common stock, including up to 261,933 dividend shares, for resale by existing investors under a new prospectus.
The shares consist of stock issuable upon conversion of Series Y preferred shares, exercise of related warrants, and stock dividends. As of February 3, 2026, 1,593,516 shares were outstanding, so full issuance would significantly increase the share count and dilute existing holders. The company recently completed a 1-for-19 reverse stock split, discontinued its BX004 cystic fibrosis program, and its Israeli subsidiary entered insolvency proceedings, leaving BiomX without operational control of that unit. To raise capital, BiomX completed a private placement of 3,300 Series Y preferred shares, initially convertible at $2.00 per share and carrying a 15% annual dividend, plus warrants for 3,300,000 shares at $2.50. The preferred and warrants include ownership caps, dividend step-ups after triggering events, redemption rights, and restrictive covenants that can limit new debt and equity issuance, while warrant exercises for cash could provide general corporate funding.